VISION UND MISSION
Wir setzen uns dafür ein, das Leben von Menschen durch Arzneimittel zu verbessern, die RNA hochpräzise editieren.-
Unsere Vision: Fortschritte in der Genetik nutzen, um Medikamente zu entwickeln, die die menschliche Gesundheit verbessern.
Unsere Mission: Als das führende Unternehmen im Bereich RNA-Editing , liefern wir Präzisionstherapien für Patienten mit seltenen und häufigen Krankheiten.
„Bei AIRNA entwickeln wir hochwirksame RNA-Editing-Therapeutika, um Patienten, die derzeit nur begrenzte Optionen haben, mehr Hoffnung zu geben. Die Leidenschaft, der Einsatz und umfassende Expertise unseres Teams kombiniert mit den von uns generierten Resultaten, geben mir großes Vertrauen in unseren Ansatz.“
Victor De Jesus
Associate Scientist
„Als jemand, dessen Leben sich dank medizinischer Durchbrüche grundlegend verändert hat, ist es ein Privileg, Teil eines Unternehmens zu sein, das eine Vorreiterrolle im Bereich RNA-Editing übernimmt und jenen Patienten hilft, deren Therapiebedarf nicht gedeckt ist.“
Sruthi V. Hindupur
Senior Scientist
Dr. Rodger Novak
Board Chair
Arch Venture Partners
Forbion
Venrock
RTW
Cambria Alpha-Cobb, JD, PhD
Head of Intellectual Property
Nextech
ND Capital
Dr. Robert Altshuler
Director, Bioinformatics
Kevin Baker, PhD
Senior Scientist, Toxicology
Peter Borsos
Senior Research Associate
Dr. Namita Bisaria
Head of Research Strategy and Operations
Theresa Bosch
Research Associate
Dr. Elisangela Bressan
Associate Principal Scientist
Maegan Brunelle
Senior Accounting Manager
Josh Brumm
Forbion
Martina Buttschardt
Senior Research Associate
Li-Hao Chang
Scientist
Dr. Aindrila Chatterjee
Senior Scientist
Chien-Ju Chen, PhD
Senior Scientist
Arthur de Garidel-Thoron, JD
Head of Business Development
Dr. Charles Conover
Vice President, Program Management
Victor De Jesus
Scientist
Anand Deshpande
Director, GxP Quality Assurance
Allison Dorval
Chief Financial Officer
Dr. Eva-Maria Duerr
Senior Scientist
Dr. Jacob S. Elkins
Chief Medical Officer
Kris Elverum
President and Chief Executive Officer
Kris Elverum
President and Chief Executive Officer, AIRNA
Dr. Juri Eyberg
Senior Scientist
Kat Feldmann
Senior Executive Assistant
Patrick Foster, PhD
SVP, Technical Operations
Ina Gerber
Associate Director, HR & Finance
Veronica Giachin
Senior Research Associate
Dr. Hyun Gyung Jang
Director DMPK & Clinical Pharmacology
Dr. Sruthi V. Hindupur
Senior Scientist
Heather Hirsch, PhD
SVP, Translational Sciences
Laleh Jafarpour, PhD
Associate Director, CMC
Dr. Inga Jarmoskaite
Associate Principal Scientist
Tamara Joseph, JD
Chief Legal Officer
Sean Kendall, MS
ARCH Venture Partners
Dr. Robin Klimek
Senior Scientist
Kaiko Kunii
In Vivo Pharmacologist
Dr. Jin Billy Li
Stanford University
Dr. Konstantin Licht
Associate Principal Scientist
Dr. Dirk Lindenblatt
Senior Scientist
Catherine Lovella
Research Associate
Aline Mack
Research Associate
Kristyn McCandless, JD
Director, Legal
Dr. Tobias Merkle
Vice President, Platform
Dr. Daniella Mizurini
Associate Principal Scientist
Dr. Melissa McCracken
Nextech
Dr. Jürgen Müller
Managing Director Tübingen and Head of Chemistry
Dr. Angelika Oswald
Senior Scientist
Damla Ozen
Head of IT
Marija Pejić
Research Associate
Aakash Parikh
Lab Manager
Maria Popovici-Muller
Senior Research Associate
Dr. Elena Poser
Principal Scientist
Edgar Ramos
Financial Controller
Dr. Lange Yakubu Saleh
Scientist
Dr. Sriram Sathy
Chief Scientific Officer
Carolin Schlitz
Research Associate
Dr. Anindya Sen
Vice President, Preclinical Development
Sebastian Sonnenstuhl
Lab Operation Manager
Dr. Devyn Smith
Arbor Bio
Dr. Luise Stafforst
Senior EHS & QC Analyst
Dr. Thorsten Stafforst
Universität Tübingen
Dr. Thorsten Stafforst
Universität Tübingen
Kristina Storey
SVP, Head of Regulatory Affairs
Niru Subramanian
Chief Operating Officer
Dr. Stephen Su
Senior Director, Target Validation
Dr. Rewati Tappu
Senior Scientist
Colleen Tucker
Head of People
Dr. Paul Vogel
Vice President, Discovery
Dr. Paul Vogel
Vice President, Discovery
Christopher Volkert
Senior Research Associate
Joyce Zhao, PhD
Director, Analytical Development